ALX Oncology says Phase 2 ASPEN-06 study shows 40.3% response rate

Company says results were already published in Nature Medicine. It also said it will not pursue a U.S. registrational Phase 3 path in gastric cancer and will keep a mid-2027 topline readout target for ASPEN-09-Breast.